TRV GP III’s Pliant Therapeutics PLRX Stock Holding History

TRV GP III’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$6.14M	Hold	339,160	–	–	100%	1
2023 Q3	$5.88M	Hold	339,160	–	–	100%	1
2023 Q2	$6.15M	Sell	339,160 -1,500,000	-82%	-$35.5M	33.71%	2
2023 Q1	$48.9M	Hold	1,839,160	–	–	58.97%	1
2022 Q4	$35.6M	Sell	1,839,160 -2,000,000	-52%	-$41.8M	27.86%	2
2022 Q3	$80.2M	Sell	3,839,160 -2,000,000	-34%	-$38.3M	35.02%	1
2022 Q2	$46.8M	Hold	5,839,160	–	–	19.13%	2
2022 Q1	$40.9M	Hold	5,839,160	–	–	11.11%	4
2021 Q4	$78.8M	Hold	5,839,160	–	–	19.73%	2
2021 Q3	$98.6M	Hold	5,839,160	–	–	18.71%	3
2021 Q2	$170M	Hold	5,839,160	–	–	29.69%	2
2021 Q1	$230M	Hold	5,839,160	–	–	29.05%	2
2020 Q4	$133M	Hold	5,839,160	–	–	11.39%	4
2020 Q3	$132M	Hold	5,839,160	–	–	11.11%	4
2020 Q2	$190M	Buy	+5,839,160	New	+$155M	27.66%	2

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

TRV GP III's PLRX Position: Q4 2023 in Review

TRV GP III held its Pliant Therapeutics (PLRX) position steady in Q4 2023 at 339,160 shares worth $6.14M. The position accounts for 100% of the portfolio, ranked #1.

TRV GP III first reported a position in PLRX in Q2 2020 and has held it in 15 quarters since. The position peaked at $230M in Q1 2021. 134 funds tracked by Wall St. Rank hold PLRX as of Q4 2023.

TRV GP III held 339,160 shares of Pliant Therapeutics worth $6.14M as of Q4 2023.
TRV GP III left its Pliant Therapeutics share count unchanged in Q4 2023.
Pliant Therapeutics made up 100% of TRV GP III's portfolio in Q4 2023, its #1 holding.
TRV GP III first reported a position in Pliant Therapeutics in Q2 2020 and has held it in 15 quarters since.
TRV GP III's Pliant Therapeutics position peaked at $230M in Q1 2021.
134 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2023.

Based on TRV GP III's 13F filing for Q4 2023, filed 14 Feb 2024.